이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Cardiol Therapeutics 관리

관리 기준 확인 1/4

Cardiol Therapeutics' CEO는 David Elsley, Jan2017 에 임명되었습니다 의 임기는 7.42 년입니다. 총 연간 보상은 CA$ 748.10K, 70.2% 로 구성됩니다. 70.2% 급여 및 29.8% 보너스(회사 주식 및 옵션 포함). 는 CA$ 3.17M 가치에 해당하는 회사 주식의 1.69% 직접 소유합니다. 3.17M. 경영진과 이사회의 평균 재임 기간은 각각 4.7 년과 2.4 년입니다.

주요 정보

David Elsley

최고 경영자

CA$748.1k

총 보상

CEO 급여 비율	70.2%
CEO 임기	7.7yrs
CEO 소유권	1.7%
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	2.7yrs

최근 관리 업데이트

Recent updates

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Sep 12

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

May 01

Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Jan 06

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

Sep 13

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

May 24

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Dec 09

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Aug 19

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Apr 18

Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Jan 03

CEO 보상 분석

David Elsley 의 보수는 Cardiol Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CA$29m
Mar 31 2024	n/a	n/a	-CA$30m
Dec 31 2023	CA$748k	CA$525k	-CA$28m
Sep 30 2023	n/a	n/a	-CA$28m
Jun 30 2023	n/a	n/a	-CA$30m
Mar 31 2023	n/a	n/a	-CA$29m
Dec 31 2022	CA$654k	CA$525k	-CA$31m
Sep 30 2022	n/a	n/a	-CA$30m
Jun 30 2022	n/a	n/a	-CA$32m
Mar 31 2022	n/a	n/a	-CA$32m
Dec 31 2021	CA$1m	CA$455k	-CA$32m
Sep 30 2021	n/a	n/a	-CA$35m
Jun 30 2021	n/a	n/a	-CA$30m
Mar 31 2021	n/a	n/a	-CA$27m
Dec 31 2020	CA$517k	CA$450k	-CA$21m
Sep 30 2020	n/a	n/a	-CA$14m
Jun 30 2020	n/a	n/a	-CA$13m
Mar 31 2020	n/a	n/a	-CA$13m
Dec 31 2019	CA$450k	CA$450k	-CA$14m
Sep 30 2019	n/a	n/a	-CA$20m
Jun 30 2019	n/a	n/a	-CA$21m
Mar 31 2019	n/a	n/a	-CA$19m
Dec 31 2018	CA$713k	CA$363k	-CA$16m

보상 대 시장: David 의 총 보상 ($USD 555.53K )은 Canadian 시장( $USD 175.74K ).

보상과 수익: 회사가 수익성이 없는 동안 David 의 보상이 증가했습니다.

CEO

David Elsley

7.7yrs

테뉴어

CA$748,100

보상

Mr. David G. Elsley, MBA, has been the President, Chief Executive Officer and Director of Cardiol Therapeutics Inc since January 19, 2017. Mr. Elsley is a business leader with a proven track record of deve...

리더십 팀

이름	위치	테뉴어	보상	소유권
David Elsley	President	7.7yrs	CA$748.10k	1.72% CA$ 3.3m
Christopher Waddick	CFO, Corporate Secretary & Director	6.1yrs	CA$294.80k	0.16% CA$ 305.8k
Bernard Lim	Chief Operating Officer	3.8yrs	CA$515.90k	0.043% CA$ 83.4k
Andrew Hamer	Chief Medical Officer & Head of Research & Development	3.5yrs	CA$746.56k	0.45% CA$ 874.0k
Trevor Burns	Investor Relations	no data	데이터 없음	데이터 없음
John Geddes	Vice President of Corporate Development	less than a year	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

경험이 풍부한 관리: CRDL 의 관리팀은 경험 ( 4.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
David Elsley	President	7.7yrs	CA$748.10k	1.72% CA$ 3.3m
Christopher Waddick	CFO, Corporate Secretary & Director	2.3yrs	CA$294.80k	0.16% CA$ 305.8k
Colin Stott	Independent Director	4.8yrs	CA$60.00k	0.20% CA$ 396.2k
Jennifer Chao	Independent Director	2.5yrs	CA$76.92k	0.14% CA$ 278.0k
Peter Pekos	Independent Director	6.8yrs	CA$58.00k	0.67% CA$ 1.3m
Michael Willner	Independent Director	3yrs	CA$71.52k	1.22% CA$ 2.4m
Paul Ridker	Member of Scientific Advisory Board	2.7yrs	데이터 없음	데이터 없음
Bruce McManus	Member of Scientific Advisory Board	2.7yrs	데이터 없음	데이터 없음
Teri Loxam	Independent Director	2.3yrs	CA$82.32k	0.17% CA$ 333.6k
Guillermo Torre-Amione	Independent Chairman	6.1yrs	CA$112.68k	0.32% CA$ 613.0k
Joseph Hill	Member of Scientific Advisory Board	2.7yrs	데이터 없음	데이터 없음

2.7yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: CRDL 의 이사회는 경험(평균 재직 기간 2.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Cardiol Therapeutics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

President recently bought CA$138k worth of stock

Cardiol Therapeutics Inc., Annual General Meeting, Jul 26, 2024

Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2023

High number of new and inexperienced directors

Cardiol Therapeutics Inc. Announces Board Appointments

High number of new and inexperienced directors

Recent updates

Cardiol Therapeutics Inc. Achieves Target Patient Enrollment in its Phase II Archer Trial Investigating CardiolRxTM for Acute Myocarditis

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Cardiol Therapeutics Announces Completion of the Maveric Phase II Study in Recurrent Pericarditis with Results to Be Presented At the American Heart Association Scientific Sessions 2024

President recently bought CA$138k worth of stock

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

Cardiol Therapeutics Inc., Annual General Meeting, Jul 26, 2024

New major risk - Share price stability

New minor risk - Share price stability

Cardiol Therapeutics Inc. Announces It Has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Cardiol Therapeutics Inc. Announces Massachusetts General Hospital as the 8th Major Medical Centre Participating in MAvERIC-Pilot

New minor risk - Shareholder dilution

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Cardiol Therapeutics Inc. Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in Model of Heart Failure with Preserved Ejection Fraction

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in Archer, A Phase II Trial of Cardiolrx™ for the Treatment of Acute Myocarditis

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to CA$0.37 loss

Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2023

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Cardiol Therapeutics Inc. Announces First Patient Enrolled in Phase II Study Evaluating Cardiolrx for the Treatment of Recurrent Pericarditis

Cardiol Therapeutics Inc. Announces the Initiation of a Phase II Open-Label Pilot Study (NCT05494788), to Investigate the Tolerance, Safety, and Efficacy of CardiolRx in Patients with Recurrent Pericarditis

No longer forecast to breakeven

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

High number of new and inexperienced directors

Price target increased to CA$4.50

Cardiol Therapeutics Inc. Announces Study Results Demonstrating Protective Effects of Cardiolrx in A Model of Acute Pericarditis

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating Cardiolrx Inhibits

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Consensus forecasts updated

Cardiol Therapeutics Inc. Announces First Patient Enrolled in Archer, A Phase II Clinical Trial of Cardiolrx(TM) for Treatment of Acute Myocarditis

Consensus forecasts updated

Consensus forecasts updated

Cardiol Therapeutics Inc. Announces Board Appointments

Cardiol Therapeutics Announces FDA Investigational New Drug Application Authorization for Multicenter Phase II Open-Label Pilot Study of Cardiolrx for Recurrent Pericarditis

Price target decreased to CA$7.50

High number of new and inexperienced directors

Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2022

We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Independent Chairman recently bought CA$121k worth of stock

Price target decreased to CA$10.83

Cardiol Therapeutics Inc. Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments in Lancer Trial

High number of new and inexperienced directors

No longer forecast to breakeven

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Independent Director exercised options to buy CA$97k worth of stock.

Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (Ind) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Cardiol Therapeutics Common Shares Class A Deleted from Other OTC

High number of new directors

Price target increased to CA$9.57

Cardiol Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 22.0032 million.

Cardiol Therapeutics Announces First Patient Enrolled in Lancer, A Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with Covid-19

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Consensus forecasts updated

Independent Director exercised options to buy CA$88k worth of stock.

Independent Director recently bought CA$99k worth of stock

New 90-day high: CA$3.72

Cardiol Therapeutics Inc Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase Ii/Iii Outcomes Trial in High-Risk Patients Hospitalized with Covid-19

Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company's Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with Covid-19

New 90-day low: CA$2.38

Price target raised to CA$5.28

New 90-day high: CA$3.44

U.S. Food and Drug Administration Approves Cardiol Therapeutics Inc.'S Investigational New Drug Application to Commence A Phase II/III of CardiolRx

New 90-day high - CA$2.94

New 90-day low - CA$2.22

CEO 보상 분석